• 1
    Daughaday WH & Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocrine Rev 1989; 10: 68 91
  • 2
    Baserga R, Resnicoff M, D’Ambrosio C, Valentinis B. The role of the IGF-I receptor in apoptosis. Vitamins Hormones 1997; 53: 65 98
  • 3
    Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 1992; 65: 311 20
  • 4
    Kaicer EK, Blat C, Harel L. IGF-I and IGF-binding proteins: stimulatory and inhibitory factors secreted by human prostatic adenocarcinoma cells. Growth Factors 1991; 4: 231 7
  • 5
    Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 1993; 53: 1102 6
  • 6
    Cohen P, Peehl DM, Lamson G, Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endoc Metab 1991; 73: 401 7
  • 7
    Ritchie CK, Andrews LR, Thomas KG, Tindall DJ, Fitzpatrick LA. The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. Endocrinology 1997; 138: 1145 50
  • 8
    Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endoc Metab 1993; 76: 1031 5
  • 9
    Kanety H, Madjar Y, Dagan Y et al. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endoc Metab 1993; 77: 229 33
  • 10
    Ho PJ & Baxter RC. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endoc 1997; 46: 333 42
  • 11
    Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997; 76: 1115 8
  • 12
    Chan JM, Stampfer MJ, Giovannucci E et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563 6
  • 13
    Zapf J, Schmid C, Froesch ER. Biological and immunological properties of insulin-like growth factors (IGF) I and II. Clin Endoc Metab 1984; 13: 3 30
  • 14
    Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endoc Metab 1992; 75: 1046 53
  • 15
    Juul A, Bang P, Hertel NT et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endoc Metab 1994; 78: 744 52
  • 16
    Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE. The ratio between serum levels of insulin-like growth factor (IGF)-1 and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endoc 1994; 41: 85 93
  • 17
    Goodman-Gruen D & Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. Am J Epidemiol 1997; 145: 970 6
  • 18
    Unterman TG, Vazquez RM, Slas AJ, Martyn PA, Phillips LS. Nutrition and somatomedin. XIII. Usefulness of somatomedin-C in nutritional assessment. Am J Med 1985; 78: 228 34
  • 19
    Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocrine Rev 1994; 15: 80 101
  • 20
    Clemmons DR, Klibanski A, Underwood LE et al. Reduction of plasma immunoreactive somatomedin C during fasting in humans. J Clin Endoc Metab 1981; 53: 1247 50
  • 21
    Landin-Wilhelmsen K, Wilhelmsen L, Lappas G et al. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endoc 1994; 41: 351 7
  • 22
    Poehlman ET & Copeland KC. Influence of physical activity on insulin-like growth factor-I in healthy younger and older men. J Clin Endoc Metab 1990; 71: 1468 73
  • 23
    Kirschner BS & Sutton MM. Somatomedin-C levels in growth-impaired children and adolescents with chronic inflammatory bowel disease. Gastroenterol 1986; 91: 830 6
  • 24
    Lecornu M, David L, Francois R. Low serum somatomedin activity in celiac disease. A misleading aspect in growth failure from asymptomatic celiac disease. Helvetica Paediatrica Acta 1978; 33: 509 16
  • 25
    Counts DR, Gwirtsman H, Carlsson LM, Lesem M, Cutler GB. The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins. J Clin Endoc Metab 1992; 75: 762 7
  • 26
    Wu JC, Daughaday WH, Lee SD et al. Radioimmunoassay of serum IGF-I and IGF-II in patients with chronic liver diseases and hepatocellular carcinoma with or without hypoglycemia. J Lab Clin Med 1988; 112: 589 94
  • 27
    Maes M, Underwood LE, Ketelslegers JM. Low serum somatomedin-C in insulin-dependent diabetes: evidence for a postreceptor mechanism. Endocrinology 1986; 118: 377 82
  • 28
    Clemmons DR & Underwood LE. Somatomedin-C/insulin-like growth factor I in acromegaly. Clin Endoc Metab 1986; 15: 629 53